March 2023

Categories:development course
Author:InnoModels
Origin:InnoModels
Time of issue:2023-03-29 15:48
Views:

(Summary description)Obtained Laboratory Animal Production License

March 2023

(Summary description)Obtained Laboratory Animal Production License

Categories:development course
Author:InnoModels
Origin:InnoModels
Time of issue:2023-03-29 15:48
Views:

Information

Obtained Laboratory Animal Production License

Previous: March 2023

Next: December 2022

Previous: March 2023

Next: December 2022

Overview of iHuPBMC-T Technology from InnoModels Biotechnology [ 2024-11-27 ]

In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.

Introducing the Patent of PBMC Immune System Reconstruction Capability Detection Method and Application by InnoModels Biotechnology [ 2024-11-25 ]

Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models

InnoModels Biotechnology ELISpot platform: a powerful tool to precisely analyze the immune response [ 2024-10-18 ]

With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality

Advantages of InnoModels' ADCC Platform [ 2024-10-17 ]

InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment

InnoModels Biotechnology CDC Platform [ 2024-10-16 ]

In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment

InnoModels Biotechnology IC50 Platform: An Innovative Force for Drug Discovery and Life Science Research [ 2024-10-15 ]

In the vast field of drug discovery and life science research, InnoModels Biotechnology (Beijing) Co., Ltd. is gradually becoming a leader in the industry with its IC50 platform. The platform not only integrates advanced detection technologies, abundant cell resources and strict quality control system, but also provides researchers with efficient and reliable experimental solutions through continuous innovation and optimization.

…

Tel 15010000264
E-mail limy@imodels.tech
Tel 13810723384
Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL：15010000264 13810723384

Email：cndw@imodels.tec

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company